<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clopidogrel resistance and clopidogrel treatment failure</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clopidogrel resistance and clopidogrel treatment failure</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Clopidogrel resistance and clopidogrel treatment failure</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Udaya S Tantry, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Charles H Hennekens, MD, FACPM, FACC</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">James L Zehnder, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul A Gurbel, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lawrence LK Leung, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Donald Cutlip, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd F Dardas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 09, 2021.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">Clopidogrel</a>, an oral platelet P2Y<sub>12 </sub>receptor blocker, is used with <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> in patients who undergo coronary artery stenting or who have an acute coronary syndrome (ACS) to reduce the risk of subsequent cardiovascular events such as stent thrombosis or recurrent ACS. Nonetheless, adverse cardiovascular events occur despite the use of dual antiplatelet therapy and are partly attributable to the variable pharmacodynamics of aspirin and P2Y<sub>12 </sub>receptor blockers. </p><p>This topic will address whether there is a clinical role for screening patients for P2Y<sub>12</sub> drug resistance and the management of patients who have clinical events despite <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> therapy. </p><p>The issues concerning <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> nonresponse and resistance are presented separately. (See  <a class="medical medical_review" href="/d/html/16946.html" rel="external">"Nonresponse and resistance to aspirin"</a>.)</p><p>The indications for P2Y<sub>12</sub> inhibitor use for the treatment of coronary artery disease are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/94.html" rel="external">"Acute ST-elevation myocardial infarction: Antiplatelet therapy", section on 'Patients receiving primary PCI'</a> and  <a class="medical medical_review" href="/d/html/1576.html" rel="external">"Antithrombotic therapy for elective percutaneous coronary intervention: General use", section on 'P2Y12 receptor blockers'</a> and  <a class="medical medical_review" href="/d/html/95.html" rel="external">"Acute non-ST-elevation acute coronary syndromes: Early antiplatelet therapy"</a> and  <a class="medical medical_review" href="/d/html/1572.html" rel="external">"Long-term antiplatelet therapy after coronary artery stenting in stable patients", section on 'Information for patients'</a>.)</p><p>The indications for P2Y<sub>12</sub> inhibitor use in stroke are discussed separately. (See  <a class="medical medical_review" href="/d/html/1086.html" rel="external">"Long-term antithrombotic therapy for the secondary prevention of ischemic stroke", section on 'Clopidogrel'</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">DEFINITIONS</span></p><p>"<strong>Nonresponsiveness</strong>" to an antiplatelet drug is a pharmacodynamic phenomenon where there is no clinically meaningful change in platelet function after treatment. In studies employing light transmittance aggregometry, a change in maximal aggregation ≤10 percent from baseline, using adenosine diphosphate (ADP) as the agonist, is defined as "resistance." The percent change between pretreatment and on-treatment platelet function (ie, "responsiveness") can be categorized as "nonresponsive" (≤10 percent), "hypo-responsive" (10 to 20 percent), or "responsive" (&gt;20 percent).</p><p><strong>Heightened platelet reactivity (HPR)</strong>, also called <strong>high on-treatment platelet reactivity</strong>, to ADP during <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> therapy indicates persistent suboptimal response of the P2Y<sub>12</sub> receptor (clopidogrel target). It is based on one measurement of on-treatment platelet reactivity. Usually, the cut points of HPR have been linked to clinical risk of thrombosis based on nonrandomized comparisons of stented patients. The evidence to support these cut points is described elsewhere. (See <a class="local">'HPR and thrombotic events'</a> below.)</p><p><a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">Clopidogrel</a><strong> treatment failure</strong> is best defined as the occurrence of a thrombotic event/ischemic event during clopidogrel therapy in patients with HPR. Treatment failure may result from patient noncompliance and/or inadequate antiplatelet response to clopidogrel. As multiple signaling pathways mediate platelet activation and the occurrence of thrombotic events, a treatment strategy directed against a single pathway, cannot be expected to prevent the occurrence of all events. </p><p>In this context, not all ischemic events in patients taking <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> may be due to lack of clopidogrel pharmacodynamic effect. There are multiple mechanisms involved in the genesis of a thrombotic event that may overcome the pharmacodynamic effects of clopidogrel. Therefore, a patient taking clopidogrel after stenting may have a new ischemic event in the presence of potent response to clopidogrel as measured by a platelet function assay.</p><p class="headingAnchor" id="H7651360"><span class="h1">PREVALENCE</span><span class="headingEndMark"> — </span>It has been estimated that between 16 and 50 percent of patients treated with <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> have high on-treatment platelet reactivity (HPR) [<a href="#rid1">1</a>]. HPR is dependent on the cut-off value used for each assay: the higher the cut-off, the lower the percent of patients with HPR. In addition, poor biologic response is determined by factors other than HPR. (See <a class="local">'Potential explanations'</a> below.)</p><p><a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">Clopidogrel</a> response variability was initially demonstrated by measuring adenosine diphosphate-induced (ADP) platelet aggregation, as well as p-selectin and activated GP IIb/IIIa expression, at baseline and serially for 30 days after stenting in patients treated with a 300 mg clopidogrel load followed by 75 mg daily therapy. Some patients had no demonstrable antiplatelet effect; when the absolute difference between pre- and post-treatment platelet aggregation was ≤10 percent, patients were labelled regarded as "resistant" [<a href="#rid2">2</a>]. The prevalence of resistant patients was 31 percent at day five post-stenting, and it fell to 15 percent at day 30.  (<a class="graphic graphic_figure graphicRef87715" href="/d/graphic/87715.html" rel="external">figure 1</a>).</p><p>In addition, the level of platelet reactivity early after a standard <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> regimen for coronary stenting was directly related to the pre-treatment reactivity. It has been reported that patients treated with clopidogrel (or <a class="drug drug_general" data-topicid="9533" href="/d/drug information/9533.html" rel="external">prasugrel</a>) who were hyper-responsive to ADP before treatment were likely to be hyper-responsive to ADP during platelet P2Y<sub>12</sub> receptor blocker treatment [<a href="#rid3">3,4</a>].</p><p>A reduction in platelet reactivity over time (after initiation of therapy) has been observed in some [<a href="#rid5">5-8</a>], but not all [<a href="#rid9">9</a>], studies. For example, two studies have shown a decrease in the prevalence of high on-treatment platelet reactivity of up to 50 percent at day 30 compared to day one post-stenting [<a href="#rid2">2,6,7</a>]. The reason for this time-dependent decrease is not clear. </p><p class="headingAnchor" id="H22"><span class="h1">POTENTIAL EXPLANATIONS</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">Clopidogrel</a> response variability has been attributed to variability in active metabolite generation that is caused by: variable absorption, which is influenced by an <em>ABCB1 </em>gene polymorphism [<a href="#rid1">1,10</a>]; functional variability in <em>CYP</em> isoenzyme activity, which is influenced by single nucleotide polymorphisms (SNPs); and drug-drug interactions. The latter two are discussed below.</p><p class="headingAnchor" id="H7652238"><span class="h2">Variation in clopidogrel metabolism</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">Clopidogrel</a> is a pro-drug that requires conversion into an active metabolite for biologic activity after oral administration. Approximately 85 percent of absorbed clopidogrel is hydrolyzed by human carboxylesterase-1 into an inactive carboxylic acid metabolite, and 15 percent is metabolized into an active metabolite by hepatic cytochrome P450 (CYP). Hepatic biotransformation involves a two-step oxidative process. In the first step, the thiophene ring of clopidogrel is oxidized to form 2-oxo-clopidogrel by CYP2C19, CYP1A2, and CYP2B6. In the second step, CYP3A4, CYP2B6, CYP2C19, and CYP2C9 catalyze the formation of the active metabolite (<em>R</em>-130964). It has been proposed that CYP2C19 is the major enzyme involved in the generation of clopidogrel active metabolite [<a href="#rid11">11</a>].</p><p>Among several polymorphisms of CYP2C19, the two most frequent variants associated with loss-of-function (LoF<em> </em>SNPs) are CYP2C19*2<em>, </em>a G681A mutation in exon 5 resulting in an aberrant splice site leading to the production of a truncated, nonfunctioning protein and CYP2C19*3, a G636A mutation in exon 4 resulting in a premature stop codon [<a href="#rid12">12-15</a>]. The <em>*</em>17 variant is associated with increased gene transcription and increased enzyme function. The prevalence of LoF SNPs varies with race; the prevalence in Eastern Asian populations is up to 65 percent, whereas it is approximately 30 percent in White populations [<a href="#rid16">16</a>].</p><p class="headingAnchor" id="H28"><span class="h2">Interaction with other drugs</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">Clopidogrel</a> metabolism is potentially influenced by concomitantly administered agents, such as proton pump inhibitors (PPIs), calcium channel blockers (CCBs), or <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>, which inhibit or enhance CYP activity or compete with clopidogrel during hepatic cytochrome P450-mediated metabolism [<a href="#rid1">1</a>]. Although the influence of these interactions on clopidogrel pharmacokinetics and pharmacodynamics has been reported, no prospective study has conclusively demonstrated a clinically important effect of these drugs in patients treated with clopidogrel. </p><p>In addition, demographic variables such as age, renal failure, diabetes, and body mass index also influence the platelet response to adenosine diphosphate (ADP) by either directly affecting platelet function or by affecting <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> metabolism. The final platelet reactivity phenotype and clinical outcomes of patients treated with clopidogrel is the result of all of these influences [<a href="#rid1">1</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drugs without clinically meaningful interaction</strong> –<strong> </strong>Some drugs could cause an interaction with <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a>, but trials or studies do not support a clinically important interaction. These drugs include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Statins</strong> – Although some studies have suggested a possible association between lipid soluble statin administration and pharmacodynamic effects of <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a>, the clinical relevance of these pharmacodynamics findings has not been demonstrated. Although such a relationship may be explained by the fact that some statins are metabolized by some of the same pathways as clopidogrel, the totality of evidence suggests that clinicians need not preferentially prescribe any particular statin with coadministration of clopidogrel [<a href="#rid17">17-19</a>]. (See  <a class="medical medical_review" href="/d/html/4564.html" rel="external">"Statins: Actions, side effects, and administration", section on 'Drug interactions'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Proton pump inhibitors</strong> – In most patients, we believe that PPIs and <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> can be used together. We agree with the 2009 US Food and Drug Administration notice that suggests that patients who take clopidogrel should consult with their clinician if they are taking a PPI or considering PPI use [<a href="#rid20">20,21</a>]. Despite the known pharmacodynamic interaction between PPIs and clopidogrel, which decreases the antiplatelet effect of clopidogrel, the available evidence suggests that PPIs do not decrease the clinical efficacy of clopidogrel [<a href="#rid22">22-26</a>].</p><p></p><p class="bulletIndent2">Examples of studies supporting this approach include the following:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In a systematic review of published data, simultaneous use of a P2Y<sub>12</sub> inhibitor and a PPI did not significantly increase the risk of major adverse cardiovascular events (4.5 versus 4.7 percent in the PPI group; relative risk [RR] 0.99, 95% CI 0.76-1.28) [<a href="#rid26">26</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In one of the largest trials in the meta-analysis, 3761 patients treated with <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> were randomly assigned to either <a class="drug drug_general" data-topicid="9718" href="/d/drug information/9718.html" rel="external">omeprazole</a> or placebo [<a href="#rid24">24</a>]. There was no significant difference in cardiovascular events (4.9 versus 5.7 percent with placebo; hazard ratio [HR] 0.99, 95% CI 0.68-1.44) and a lower rate of gastrointestinal bleeding in patients assigned to omeprazole (1.1 versus 2.9 percent with placebo; HR 0.34, 95% CI 0.18-0.63).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Calcium channel blockers</strong> – CCBs inhibit CYP3A4, and there has been a concern that they may decrease the efficacy of <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a>. Some [<a href="#rid27">27,28</a>], but not all [<a href="#rid29">29-31</a>], studies have suggested a possible deleterious impact of CCB on clopidogrel efficacy. Based on the current totality of evidence, we do not recommend the restriction of CCB use in patients who are prescribed clopidogrel.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drugs with uncertain clinical interaction – </strong>Examples of drugs that can alter the metabolism of <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> but whose clinical interaction is not well-established include:</p><p></p><p class="bulletIndent1">Drugs that may increase the activity of <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> by inducing CYP P450 enzymes:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">Rifampin</a> [<a href="#rid32">32,33</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>St. John’s wort [<a href="#rid34">34</a>]</p><p></p><p class="bulletIndent1">Drugs that may decrease the activity of <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> by inhibiting CYP P450 enzymes:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Polyunsaturated omega-3 fatty acids [<a href="#rid35">35</a>]</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9418" href="/d/drug information/9418.html" rel="external">Erythromycin</a>, troleandomycin</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8589" href="/d/drug information/8589.html" rel="external">Ketoconazole</a></p><p></p><p class="headingAnchor" id="H35"><span class="h2">Diabetes mellitus</span><span class="headingEndMark"> — </span>Patients with diabetes mellitus have increased platelet activation [<a href="#rid5">5,36-38</a>] and a higher percent of circulating immature platelets [<a href="#rid39">39</a>]. These characteristics could, in theory, counteract the inhibitory effect of <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> (or <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a>) on platelets [<a href="#rid37">37,40-43</a>]. The totality of available evidence is incomplete and inconsistent [<a href="#rid44">44-48</a>].</p><p>It has been postulated that patients with diabetes mellitus may require increased doses of one or both of these agents in order to show an optimal therapeutic effect [<a href="#rid49">49</a>], or may be candidates for a more potent platelet inhibitor (eg, <a class="drug drug_general" data-topicid="9533" href="/d/drug information/9533.html" rel="external">prasugrel</a> [<a href="#rid50">50,51</a>], <a class="drug drug_general" data-topicid="16784" href="/d/drug information/16784.html" rel="external">ticagrelor</a> [<a href="#rid52">52-55</a>]). (See  <a class="medical medical_review" href="/d/html/1542.html" rel="external">"Prevalence of and risk factors for coronary heart disease in patients with diabetes mellitus", section on 'Platelet activation'</a> and  <a class="medical medical_review" href="/d/html/6683.html" rel="external">"Platelet biology and mechanism of anti-platelet drugs"</a> and  <a class="medical medical_review" href="/d/html/6683.html" rel="external">"Platelet biology and mechanism of anti-platelet drugs", section on 'Platelet receptors and their agonists'</a>.)</p><p class="headingAnchor" id="H15342101"><span class="h2">Renal insufficiency</span><span class="headingEndMark"> — </span>There is no convincing evidence chronic kidney disease (CKD) significantly influences platelet response to <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> [<a href="#rid56">56,57</a>].</p><p class="headingAnchor" id="H7653383"><span class="h2">Noncompliance</span><span class="headingEndMark"> — </span>Noncompliance with <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> therapy is common and offers a plausible explanation for the lack of clinical benefit [<a href="#rid15">15,58,59</a>]. </p><p class="headingAnchor" id="H88296422"><span class="h2">Smoking</span><span class="headingEndMark"> — </span>In subgroup analyses of randomized trials of <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> therapy, nonsmokers taking clopidogrel had less clinical benefit than did smokers taking clopidogrel. This effect is referred to as a "smoker's paradox" [<a href="#rid60">60-63</a>]. The stimulation of CYP1A2 associated with smoking enhances platelet inhibition by clopidogrel; smoking cessation reverses this effect [<a href="#rid28">28,29,42,60-62,64-67</a>]. Although this subgroup finding may be due to chance, lower clopidogrel active metabolite exposure and pharmacodynamic effects of clopidogrel in nonsmokers relative to smokers is a plausible alternative explanation for the smokers’ paradox [<a href="#rid68">68</a>]. </p><p>The magnitude of the effect of smoking on the efficacy of <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> was evaluated in a 2013 systematic review, meta-analysis, and indirect comparison of randomized trials that included nearly 75,000 patients (29 percent smokers) in which clopidogrel was compared to placebo, <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a>, or another platelet P2Y<sub>12</sub> receptor blocker [<a href="#rid63">63</a>]. Among the subgroup of smokers, patients taking clopidogrel had a 25 percent reduction in the primary composite outcome of cardiovascular death, myocardial infarction (MI), and stroke compared to the control therapy (RR 0.75, 95% CI 0.67-0.83). In the subgroup of nonsmokers, patients taking clopidogrel had a smaller 8 percent reduction (0.92, 95% CI 0.87-0.98). </p><p>Finally, it has been hypothesized, that the underlying pathobiology of thrombosis may differ between smokers and nonsmokers [<a href="#rid69">69</a>]. </p><p class="headingAnchor" id="H88678260"><span class="h1">HPR AND THROMBOTIC EVENTS</span><span class="headingEndMark"> — </span>Most, but not all, descriptive and observational analytic studies contribute to the formulation of the hypothesis of an association between "resistance" to <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> or high on-treatment platelet reactivity (HPR) and subsequent cardiovascular events after percutaneous coronary intervention (PCI) or peripheral artery intervention: </p><p class="headingAnchor" id="H441041395"><span class="h2">Platelet function and outcomes</span></p><p class="bulletIndent1"><span class="glyph">●</span>In a case series of aggregometry, 60 patients undergoing primary PCI for ST-elevation MI (STEMI) who were in the lowest quartile of <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> responsiveness at day six (compared to baseline levels) had the highest rates of ischemic events during follow-up [<a href="#rid70">70</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the PREPARE POST-STENTING study, a threshold of approximately 50 percent maximal periprocedural aggregation (with 20 micromol adenosine diphosphate [ADP]) was associated with six-month ischemic event occurrence [<a href="#rid71">71</a>]. In subsequent studies, approximately 40 percent aggregation (with 20 micromol ADP) was associated with the onset of risk for stent thrombosis occurrence and approximately 40 percent platelet aggregation (5 micromol ADP) among patients receiving long-term <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> and <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> therapy before stenting was associated with 12-month ischemic event occurrence [<a href="#rid72">72,73</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a case series of 340 patients undergoing PCI, those with high posttreatment reactivity measured by VerifyNow (&gt;235 P2Y<sub>12</sub> reaction units [PRU]) had higher rates of cardiovascular death (2.8 versus 0 percent, p = 0.04) and stent thrombosis (4.6 versus 0 percent, p = 0.004) [<a href="#rid74">74</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a case series of 1608 patients undergoing elective PCI using the Multiplate analyzer, low responders as indicated by upper quintile platelet reactivity (approximately 482 aggregation units (AU)*min) had a significantly higher risk of definite stent thrombosis and a higher mortality rate within 30 days compared with patients less than 482 AU*min [<a href="#rid75">75</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a case series of 802 consecutive patients undergoing elective PCI receiving a loading dose of 600 mg <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> followed by 75 mg daily [<a href="#rid76">76</a>], platelet aggregation was assessed immediately before PCI by optical aggregometry following 5 micromol ADP. Multivariate analysis confirmed platelet aggregation above the median level as a significant independent predictor of the 30-day composite of death, MI, and target lesion revascularization (relative risk [RR] 6.7, 95% CI 1.5-29).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>On-treatment platelet reactivity utilizing the VerifyNow P2Y<sub>12</sub> point-of-care assay was evaluated in a study of 683 patients with acute coronary syndromes (ACS) who were treated with <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> and <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> and were scheduled to undergo PCI [<a href="#rid77">77</a>]. In a multivariate model, a residual platelet reactivity (RPR) ≥240 PRU was a significant and independent predictor of cardiovascular death and nonfatal MI at 12 months (hazard ratio [HR] 2.5, 95% CI 1.3-5.1). No significant association was found between a high RPR and target vessel revascularization. A subsequent meta-analysis, which included this study, concluded that an RPR ≥230 PRU was associated with a significantly higher rate of the composite end point of death, MI, and stent thrombosis (HR 2.10, 95% CI 1.62-2.73), as well as a significantly higher rate for each of the individual end points of death, MI, and stent thrombosis [<a href="#rid78">78</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The prospective registry, ADAPT-DES, is the largest case series of platelet function study conducted, which was in patients treated with stenting. Platelet reactivity was assessed using VerifyNow point-of-care assays in 8582 patients (52 percent ACS patients) after successful PCI. HPR (&gt;208 PRU) was independently associated with 30-day definite/probable stent thrombosis (HR 3.0, p = 0.005), one-year definite/probable stent thrombosis (HR 2.49, p = 0.001), and MI (HR 1.42, p = 0.01); and two-year definite/probable stent thrombosis (adjusted HR 1.84, p = 0.009) and MI (HR 1.33, p = 0.01). In addition, &gt;208 PRU was independently associated with a lower incidence of bleeding at one year (HR 0.73, p = 0.002) and at two years (HR 0.82, p = 0.02) [<a href="#rid79">79,80</a>]. A monotonic association between successively higher PRU quintiles and two-year stent thrombosis was observed, whereas the greatest risk of clinically relevant bleeding occurred in the lowest PRU quintile, with similar risks across the four higher quintiles. These relationships remained significant in fully adjusted multivariable analyses (adjusted HR for stent thrombosis in Q5 versus Q1: 2.32, 95% CI 1.17-4.59; p = 0.02; adjusted HR for clinically relevant bleeding in Q5 versus Q1: 0.61, 95% CI 0.47-0.77; p&lt;0.001).</p><p></p><p class="bulletIndent1">ADAPT-DES provides important and relevant information to the formulation of hypotheses about patients with HPR and culprit-lesion morphology, as well as adverse plaque morphology. Specifically, three-vessel coronary artery disease, incidence of fibroatheroma, elevated percentage of plaque burden, and longer culprit lesion attenuated plaque length [<a href="#rid81">81</a>].</p><p></p><p class="bulletIndent1">Those prescribed a PPI had higher HPR (odds ratio 1.38, 95% CI 1.25-1.52; p = 0.0001) and also a greater rate of postdischarge adverse outcomes (HR 1.21, 95% CI 1.04-1.42; p = 0.02) [<a href="#rid82">82</a>]. After further analysis of patients who were treated with DAPT at two years in the ADAPT DES study (comprising 46 percent of patients), those with HPR prescribed <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> had higher rates of definite or probable stent thrombosis (adjusted HR 2.16, p = 0.003), MI (adjusted HR 1.35, p = 0.02), freedom from clinically relevant bleeding (adjusted HR 0.74, p = 0.002), and all-cause mortality (adjusted HR 1.36, p = 0.04) [<a href="#rid83">83</a>]. These results are useful to formulate but not test hypotheses and may be due, all or in part, to confounding by indication. In addition, however, they are compatible with the "therapeutic window of P2Y<sub>12</sub> inhibition" at moderately inhibited PRU to avoid the risk of ischemic event occurrences and bleeding and contribute to the formulation of the platelet hypothesis for which personalized antiplatelet therapy is being prescribed [<a href="#rid84">84</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Systemic review and meta-analysis of individual patient data on MACE outcomes using 13 prospective observational studies with 6478 clopidogrel-treated patients revealed that the strength of the association between MACE risk and platelet reactivity as measured by ADP-induced aggregation by conventional aggregometry was increased significantly (p = 0.04) with the number of risk factors present (age &gt;75 years, ACS at inclusion, diabetes, and hypertension). Platelet reactivity allowed the reclassification of 44 percent of the total population to a different risk level for the outcome of MACE, mostly in intermediate or high-risk patients [<a href="#rid85">85</a>]. In this regard, it should be noted that meta-analyses of observational studies will surely reduce the role of chance but also introduce bias and confounding as the individual studies are not randomized [<a href="#rid86">86,87</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the PRECLOP's case series of 100 patients undergoing infrainguinal angioplasty or stenting and taking <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> 75 mg daily were assessed with VerifyNow prior to the procedure [<a href="#rid88">88</a>]. At one year, the primary composite end point (death, major stroke, major amputation, target vessel revascularization, and bypass) increased with increasing quartile of PRU (4, 12, 52, and 84 percent, respectively; all p&lt;0.05 except for the first versus second quartile). </p><p></p><p>Since case series are descriptive and are hypothesis formulating but not testing, some medically managed patients do not support this hypothesis:</p><p class="bulletIndent1"><span class="glyph">●</span>In the TRILOGY randomized trial, 9326 patients with medically managed unstable angina or non-ST elevation MI were randomly assigned to treatment with either <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> or <a class="drug drug_general" data-topicid="9533" href="/d/drug information/9533.html" rel="external">prasugrel</a> and 27.5 percent of these patients were included in the platelet function substudy [<a href="#rid89">89</a>]. Platelet function was measured serially up to 30 months after randomization by the VerifyNow assay. There was only a modest, unadjusted association between on-treatment PRU values and HPR status with ischemic event occurrence that did not persist after multivariable adjustment. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the ADIRE case series of 771 stable cardiovascular outpatients, platelet reactivity to ADP was not associated with three-year major cardiovascular adverse events [<a href="#rid90">90</a>].<sup> </sup></p><p></p><p class="headingAnchor" id="H620492189"><span class="h2">Loss of function gene carriers and outcomes</span><span class="headingEndMark"> — </span>Evidence from prospective studies of P2Y<sub>12</sub> therapy suggest higher rates of cardiovascular events in patients with loss of function CYP2C19 gene variants who are taking <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> [<a href="#rid91">91-95</a>]. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>In an NIH Implementing Genomics In Practice (IGNITE) study, patients with a LoF gene variant treated with <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> had higher rates MACE after PCI. After 1 year of observation, CYP2C19 LOF allele carriers who received clopidogrel were more likely to experience a MACE than those allele carriers who received alternative therapy (adjusted HR 2.21, p = 0.021). In patients who received either <a class="drug drug_general" data-topicid="9533" href="/d/drug information/9533.html" rel="external">prasugrel</a> or <a class="drug drug_general" data-topicid="16784" href="/d/drug information/16784.html" rel="external">ticagrelor</a>, patients with a CYP2C19 LOF allele had a similar risk of MACE when compared to patients without a LOF allele (adjusted HR 0.81, 95% CI 0.48-1.35; p = 0.41) [<a href="#rid91">91</a>].  </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a meta-analysis of randomized trials designed to compare the efficacy of <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> to either <a class="drug drug_general" data-topicid="9533" href="/d/drug information/9533.html" rel="external">prasugrel</a> or <a class="drug drug_general" data-topicid="16784" href="/d/drug information/16784.html" rel="external">ticagrelor</a> in CYP219 LOF gene carriers, patients with a CYP219 LOF gene variant had a higher risk of cardiovascular events with clopidogrel than with other P2Y<sub>12</sub> inhibitors (RR 1.42, 95% CI 1.2-1.7) [<a href="#rid92">92</a>]. Patients without a LoF gene variant had a similar risk of cardiovascular events with clopidogrel or alternative P2Y<sub>12</sub> therapy (RR 1.0, 95% CI 0.8-1.25). Patients with PCI comprised 77 percent of the sample.  </p><p></p><p class="headingAnchor" id="H88677844"><span class="h1">CLINICAL MANIFESTATIONS AND DIAGNOSIS</span><span class="headingEndMark"> — </span>As mentioned above, <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> treatment failure is the occurrence of a thrombotic event/ischemic event during clopidogrel therapy in patients with heightened platelet reactivity (HPR). These events are usually stent thrombosis or recurrent acute coronary syndrome (ACS). The clinical presentations of these events are discussed separately. (See  <a class="medical medical_review" href="/d/html/87310.html" rel="external">"Coronary artery stent thrombosis: Clinical presentation and management", section on 'Clinical presentation'</a> and  <a class="medical medical_review" href="/d/html/52.html" rel="external">"Diagnosis of acute myocardial infarction"</a>.)</p><p>A definitive diagnosis of <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> treatment failure requires the finding of HPR on laboratory testing in a patient with either stent thrombosis or recurrent ACS. In most patients, we do not believe testing for clopidogrel hyporesponsiveness is necessary. If the patient appears to have been taking clopidogrel as prescribed, switching to a more potent antiplatelet is reasonable. (See <a class="local">'Management of possible clopidogrel failure'</a> below.)</p><p>If a decision is made to use one of the following tests to assess the degree of platelet P2Y<sub>12</sub> receptor inhibition (responsiveness to antiplatelet therapy), we are most comfortable with the VerifyNow P2Y<sub>12</sub> assay, as the largest body of data correlating platelet reactivity to clinical outcomes has been obtained with it. </p><p>The following laboratory methods are used to assess the degree of platelet P2Y<sub>12</sub> receptor inhibition (responsiveness to antiplatelet therapy): </p><p class="bulletIndent1"><span class="glyph">●</span>Point-of-care and near point-of-care assays: VerifyNow P2Y<sub>12</sub> assay, Multiplate Analyzer, thrombelastography with Platelet Mapping Assay, and platelet function assay-100 with collagen-adenosine diphosphate (ADP) cartridge. VerifyNow and Multiplate assays have been widely used to demonstrate the relation of HPR to clinical outcomes in observational studies. VerifyNow has been used in the main prospective clinical trials of personalized antiplatelet therapy [<a href="#rid96">96</a>]. With the VerifyNow P2Y<sub>12</sub> assay, values &gt;208 PRU are required for the finding of HPR. With Multiplate, values &gt;47 AU are required for HPR. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>ADP-induced aggregation measured by light transmittance aggregometry using platelet rich plasma. Values &gt;46 percent with 5 micromol ADP or &gt;59 percent with 20 micromol ADP are required for the finding of HPR.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>P2Y<sub>12 </sub>receptor reactivity determined by the degree of reduction in the maximal levels of vasodilator stimulated phosphoprotein (VASP) phosphorylation (P) stimulated by P<sub>GE1</sub> after the addition of ADP. VASP-P is measured by flow cytometry and is specific in determining P2Y<sub>12</sub> receptor activity. With VASP, values &gt;50 percent PRI are required for the finding of HPR.</p><p></p><p>The cut-off values presented above are derived from studies that have used receiver operating characteristic (ROC) curve analysis used to define a threshold or cut-point of on-treatment platelet reactivity associated with the optimal combination of sensitivity and specificity to identify thrombotic/ischemic risk. It should be noted that such cut-points may depend on the subset of patients studied. In fact, cut-off values have been mainly investigated in patients undergoing percutaneous coronary intervention (PCI) and different targets may be obtained in other settings depending on patient management or baseline risk profile. The consistent findings across multiple investigations support the important role of HPR in the etiology of ischemic events after PCI, including stent thrombosis, and suggest the existence of a threshold level of platelet reactivity below which ischemic events may be prevented. </p><p>The observed cut-off values for platelet reactivity noted above had a very high negative predictive value for thrombotic/ischemic event occurrence. However, the positive predictive value is low for all assays. This is consistent with the fact that although a major determinant of thrombotic events, HPR is not the sole factor responsible for these events [<a href="#rid1">1</a>].</p><p>A 2010 consensus statement proposed cut-off values based on receiver operating characteristic curve analysis for different platelet function assays to be used in future studies of personalized antiplatelet therapy [<a href="#rid1">1</a>]. A meta-analysis of studies employing the VerifyNow point-of-care assay lends further support for the potential role of monitoring of P2Y<sub>12</sub> receptor inhibitor therapy as a diagnostic marker [<a href="#rid78">78</a>]. </p><p>Taken together, these data are compatible with the hypothesis that adequate protection against ischemic events with <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> therapy might be achieved by overall low to moderate levels of post-treatment platelet reactivity. Some studies suggested that the prognostic value of HPR can be improved by the addition of classical clinical and procedural risk factors and suggested that a comprehensive algorithm including clinical as well as laboratory findings (platelet reactivity and genotype) should be considered in future personalized antiplatelet therapy investigations to optimize outcomes [<a href="#rid97">97,98</a>].</p><p class="headingAnchor" id="H88680480"><span class="h1">SCREENING</span><span class="headingEndMark"> — </span>The utility of routine screening for <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> hyporesponsiveness or nonresponsiveness is controversial [<a href="#rid99">99</a>]. In the absence of a well-established benefit of genotype-guided therapy, <strong>we do not routinely test patients for clopidogrel resistance</strong> with genetic testing to detect loss of function gene carriers (eg, CYP2C19 allele testing) or with platelet function testing to detect P2Y<sub>12</sub> resistance [<a href="#rid100">100,101</a>].</p><p>Some experts recommend routine testing based on biological plausibility and observational studies that suggest an association between genotype or platelet function and stent thrombosis. In contrast, most randomized trials do not show a benefit of genotype-guided [<a href="#rid102">102-104</a>] or platelet reactivity-guided [<a href="#rid105">105-108</a>] antiplatelet therapy. As examples: </p><p class="bulletIndent1"><span class="glyph">●</span>The TAILOR-PCI was a large trial of gene-guided antiplatelet therapy in the drug-eluting stent era [<a href="#rid102">102</a>]. In this trial, 5302 patients undergoing percutaneous coronary intervention (PCI; 84 percent for acute coronary syndrome [ACS]) and who were to receive 12 months of DAPT were randomly assigned to <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> therapy or genotype-guided therapy. In the genotype-guided arm, CYP2C19 LoF allele carriers were given <a class="drug drug_general" data-topicid="16784" href="/d/drug information/16784.html" rel="external">ticagrelor</a> and wild-type allele carriers received clopidogrel; all patients in the standard-therapy arm received clopidogrel. The primary analysis only included patients with LoF alleles, which included 903 patients in the genotype-guided group and 946 patients in the standard therapy group. Genotype-guided therapy was associated with a nonsignificant 34 percent reduction in the primary endpoint of cardiovascular death, myocardial infarction (MI), stroke, stent thrombosis, or severe recurrent ischemia at 12 months (4.0 versus 5.9 percent; hazard ratio [HR] 0.66, 95% CI 0.43-1.02). The reduction in the endpoint was primarily driven by a reduction in severe recurrent ischemia (ie, ECG changes leading to urgent revascularization without a diagnosis of MI, cardiac angina). The risk of major or minor bleeding was similar in both groups. In a prespecified sensitivity analysis that assessed repeated events, genotype-guided therapy was associated with a significant 40 percent reduction in the primary endpoint compared with standard therapy (HR 0.60, 95% CI 0.41-0.89).  </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The POPULAR GENETICS trial found that genotype-guided therapy in patients with STEMI was associated with similar rates of MACE [<a href="#rid103">103</a>]. In this trial, 1242 patients were randomly assigned to gene-guided therapy and 1246 were assigned to standard care. In the gene-guided group, LoF carriers received <a class="drug drug_general" data-topicid="9533" href="/d/drug information/9533.html" rel="external">prasugrel</a> or <a class="drug drug_general" data-topicid="16784" href="/d/drug information/16784.html" rel="external">ticagrelor</a>, while all patients in the standard therapy group received either prasugrel or ticagrelor. The rate of all-cause death, myocardial infarction, definite stent thrombosis, stroke, and bleeding were similar between groups (5.1 versus 5.9 percent in the standard therapy group; absolute rate difference 0.7 percent; 95% CI 2.0 to -0.7). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the ANTARCTIC randomized trial, 877 ACS patients aged 75 years or older who underwent coronary stenting and were treated with <a class="drug drug_general" data-topicid="9533" href="/d/drug information/9533.html" rel="external">prasugrel</a> 5 mg were randomly assigned to platelet monitoring or no monitoring groups [<a href="#rid107">107</a>]. There was no difference between the two strategies in the primary composite end point of cardiovascular death, MI, stroke, stent thrombosis, urgent revascularization, and bleeding complications at 12 months (28 percent in both groups) or the single end point of bleeding events. The chief strength of ANTARCTIC is the randomized design, but limitations include the fact that, with low-dose prasugrel, the need to intensify therapy for high platelet reactivity was uncommon in the monitoring group (approximately 4 percent). In addition, almost all of the P2Y<sub>12</sub> dose adjustments in ANTARCTIC were de-intensification from prasugrel to <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> in an attempt to reduce bleeding. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The ARCTIC trial and subsequent ARCTIC-Monitoring study did not demonstrate a clear benefit of platelet function-guided antiplatelet therapy prior to PCI or during one year of follow-up and noted high variability in agreement between platelet function assays [<a href="#rid105">105,106</a>].  </p><p></p><p class="headingAnchor" id="H38"><span class="h1">MANAGEMENT OF POSSIBLE CLOPIDOGREL FAILURE</span><span class="headingEndMark"> — </span>Patients who have stent thrombosis or an acute coronary syndrome (ACS) while taking <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> may have clopidogrel resistance or hypo-/nonresponsiveness. As no adequately powered study has clearly demonstrated that testing for clopidogrel hyporesponsiveness improves clinically important outcomes, most of our authors and reviewers do not perform these tests. </p><p>For these patients, based on studies that have shown that more potent platelet P2Y<sub>12</sub> receptor blockers (such as <a class="drug drug_general" data-topicid="16784" href="/d/drug information/16784.html" rel="external">ticagrelor</a> or <a class="drug drug_general" data-topicid="9533" href="/d/drug information/9533.html" rel="external">prasugrel</a>) lower on-treatment platelet reactivity, most of our experts switch to one of these drugs. However, two of our authors perform platelet function testing and point-of-care genetic testing to assess for <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> hyporesponsiveness in these cases and manage the patient accordingly: the finding of platelet resistance leads to a recommendation for ticagrelor or prasugrel; the finding of adequate clopidogrel effect leads to continuation of clopidogrel therapy.</p><p>None of the interventions discussed below, including the use of a more potent agent, has been shown to improve long-term clinical outcomes. </p><p class="headingAnchor" id="H265021648"><span class="h2">Acute coronary syndrome</span></p><p class="headingAnchor" id="H16062367"><span class="h3">Adjusting the loading dose</span><span class="headingEndMark"> — </span>Achieving a platelet reactivity level below high on-treatment platelet reactivity (HPR) by selectively increasing the <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> loading dose based upon laboratory evidence for clopidogrel resistance has been shown to benefit <strong>short-term</strong> outcome [<a href="#rid109">109-116</a>].</p><p>The clinical benefit of increasing the <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> loading dose on reducing the incidence of subsequent adverse cardiac events was shown in a prospective randomized trial of 162 patients scheduled to undergo percutaneous coronary intervention (PCI). Clopidogrel hypo-nonresponsiveness was defined as an in vitro vasodilator-stimulated phosphoprotein phosphorylation analysis (VASP index) &gt;50 percent after a 600 mg loading dose of clopidogrel [<a href="#rid111">111</a>]. All patients with a VASP index &gt;50 percent were randomly assigned to a control group or VASP-guided group. In the comparison group, PCI was carried out without an additional bolus of clopidogrel, whereas in the VASP-guided group, up to three additional boluses of 600 mg of clopidogrel were given in 24-hour increments. The VASP index was then assessed 12 hours after administration until an index &lt;50 percent was achieved, following which PCI was performed. The following findings were noted:</p><p class="bulletIndent1"><span class="glyph">●</span>In the VASP-guided group, 38 patients required two doses of <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> to achieve a VASP index &lt;50 percent, 14 required three doses, and 15 required four doses.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Despite a total <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> dose of 2400 mg, 11 patients (14 percent) remained "resistant" and received PCI. There were no major adverse cardiac events in this subgroup.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The number of serious adverse cardiac events (two cardiovascular deaths, four acute or subacute stent thromboses, two recurrent ACS) during the one-month follow-up was significantly less in the VASP-guided group (0 versus 8 events).</p><p></p><p class="headingAnchor" id="H10072549"><span class="h3">Adjusting the maintenance dose</span><span class="headingEndMark"> — </span>The following studies in which the maintenance dose was adjusted did not show improvement in long-term clinical outcome:</p><p class="bulletIndent1"><span class="glyph">●</span>In the GRAVITAS trial, 2214 subjects with high platelet reactivity on <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> (as measured by the VerifyNow P2Y<sub>12</sub> test) following PCI with a drug-eluting stent, were assigned at random to treatment with either standard dose (no loading dose, 75 mg/day) or high dose (600 mg loading dose, 150 mg/day thereafter) clopidogrel for 60 days [<a href="#rid6">6</a>]. The primary study end point (six-month incidence of death from cardiovascular causes, nonfatal myocardial infarction, or stent thrombosis) was virtually identical in those receiving either standard or high dose clopidogrel (2.3 percent in each group; hazard ratio 1.01; 95% CI 0.58-1.76). In addition to being underpowered, there are other potential explanations for the neutral results of GRAVITAS trial [<a href="#rid117">117</a>]. In a time-dependent analysis of GRAVITAS, &lt;208 PRU was independently associated with the 60 days primary end point (hazard ratio [HR] 0.23, 95% CI 0.05-0.98) and tended to be an independent predictor at six months (HR 0.54, 95% CI 0.28-1.04) [<a href="#rid118">118</a>]. Only a minority of patients receiving high-dose clopidogrel achieved &lt;208, indicating that high-dose clopidogrel regimen may have been sub-optimal and a more potent intervention that reduces HPR to a greater extent would have had greater potential to improve clinical outcomes given the very low event rate. In support of this hypothesis, the ELEVATE-TIMI (Escalating Clopidogrel by Involving a Genetic Strategy - Thrombolysis In Myocardial Infarction) 56 trial showed that up to 225 mg of clopidogrel might be necessary to overcome HPR in patients carrying one loss-of-function cytochrome 2C19 gene (see below). GRAVITAS enrolled a population at low absolute risk for ischemic events despite displaying HPR. The majority of patients had stable angina, were successfully treated with PCI, and periprocedural events were not included in the primary end point. The tested pharmacologic intervention was administered more than 12 hours after PCI and the associated acute vessel injury/stent deployment, which may have been too late to blunt a platelet-related incipient lesion. Finally, it is possible that a single platelet function test may not reliably reflect the effect of clopidogrel on adenosine diphosphate-induced platelet reactivity in all patients [<a href="#rid117">117</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the CREATIVE trial, 1078 patients undergoing PCI who had low responsiveness to <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a>, as assessed by thromboelastography, were randomly assigned to standard antiplatelet therapy (clopidogrel 75 mg daily plus <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> 100 mg daily), double-dose clopidogrel (clopidogrel 150 mg daily plus aspirin 100 mg daily), or adjunctive use of <a class="drug drug_general" data-topicid="8872" href="/d/drug information/8872.html" rel="external">cilostazol</a> (cilostazol 100 mg twice daily plus aspirin 100 mg daily plus clopidogrel 75 mg daily) [<a href="#rid119">119</a>]. The primary end point of the incidence of major adverse cardiac and cerebrovascular events at 18 months occurred in 14.4, 10.6, and 8.5 percent of the three groups, respectively (HR 0.72, 96% CI 0.47-1.09 and 0.55, 95% CI 0.35-0.87, comparing double-dose clopidogrel or adjunctive cilostazol, respectively). There were no significant differences in the rates of major bleeding.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The ELEVATE study of PCI demonstrated that 225 mg daily <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> is required to reduce platelet reactivity (&lt;50 platelet reactivity index as measured by VASP phosphorylation assay) in CYP2C19*2 heterozygotes to levels achieved with standard clopidogrel, 75 mg, in noncarriers [<a href="#rid120">120</a>]. Clinical outcomes were not assessed.</p><p></p><p class="headingAnchor" id="H8268853"><span class="h3">Use of alternative antiplatelet agents</span><span class="headingEndMark"> — </span>There are no randomized trials that have tested whether the substitution (for <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a>) of more potent platelet P2Y<sub>12 </sub>receptor blockers (<a class="drug drug_general" data-topicid="16784" href="/d/drug information/16784.html" rel="external">ticagrelor</a> and <a class="drug drug_general" data-topicid="9533" href="/d/drug information/9533.html" rel="external">prasugrel</a>) in patients with HPR lowers the risk of subsequent adverse cardiovascular outcomes. Since the use of these two drugs has been shown to lower on-treatment platelet reactivity, it may be prudent to adopt this strategy [<a href="#rid54">54,121,122</a>] and we believe this is a reasonable approach. Practitioners and patients should be aware of the higher risk of bleeding with these agents. </p><p>Further support for this approach derives from data summarized below:</p><p class="bulletIndent1"><span class="glyph">●</span>In a randomized, single-blind, cross-over study, <a class="drug drug_general" data-topicid="9533" href="/d/drug information/9533.html" rel="external">prasugrel</a> was more efficient in reducing platelet function compared to <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> as measured by VerifyNow P2Y<sub>12</sub> assay. The prevalence of HPR was significantly lower in all patients (7.5 versus 35.8 percent), in CYP2C19*2 carriers (5.3 versus 47.4 percent), and in noncarriers (8.8 versus 29.4 percent). In another randomized, crossover study, the same authors demonstrated that 10 mg prasugrel therapy was very effective in overcoming HPR rate compared to 150 mg clopidogrel therapy in CYP2C19*2 carriers (0 versus 100 percent) [<a href="#rid123">123</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the RAPID GENE study, 200 patients undergoing PCI were randomly assigned to either rapid point-of-care genotyping for the CYP2C19*2 allele or standard treatment. Carriers were given 10 mg <a class="drug drug_general" data-topicid="9533" href="/d/drug information/9533.html" rel="external">prasugrel</a> daily, while noncarriers and those in the standard treatment group were given 75 mg of <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> daily [<a href="#rid122">122</a>]. The primary end point was high on-treatment platelet reactivity after one week of antiplatelet therapy, which occurred in none of the 23 carriers in the genotyping group treated with prasugrel compared with 7 of the 23 carriers (30 percent) in the standard treatment group who were treated with clopidogrel. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a post-hoc subgroup analysis of data from the ONSET/OFFSET and RESPOND studies, the prevalence of high on-treatment platelet reactivity, using a number of different laboratory assays, was significantly lower for those treated with <a class="drug drug_general" data-topicid="16784" href="/d/drug information/16784.html" rel="external">ticagrelor</a> (0 to 8 percent) than for those treated with <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> (21 to 81 percent) [<a href="#rid121">121</a>]. (See  <a class="medical medical_review" href="/d/html/6683.html" rel="external">"Platelet biology and mechanism of anti-platelet drugs"</a> and  <a class="medical medical_review" href="/d/html/95.html" rel="external">"Acute non-ST-elevation acute coronary syndromes: Early antiplatelet therapy"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the TRIGER-PCI randomized trial of 212 patients with stable coronary artery disease and high on-treatment platelet reactivity undergoing PCI, a 10 mg daily dose of <a class="drug drug_general" data-topicid="9533" href="/d/drug information/9533.html" rel="external">prasugrel</a> was effective in reducing on-treatment platelet reactivity compared to 75 mg daily dose <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> [<a href="#rid108">108</a>]. However, the study was terminated early for futility because of extremely low event rates. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a randomized trial of STEMI patients undergoing PCI, two-hour post-dose, HPR (&gt;208 PRU) prevalence was 46.2 and 34.6 percent in patients treated with <a class="drug drug_general" data-topicid="16784" href="/d/drug information/16784.html" rel="external">ticagrelor</a> and <a class="drug drug_general" data-topicid="9533" href="/d/drug information/9533.html" rel="external">prasugrel</a>, respectively. Efficacy, defined as reducing platelet reactivity during the first 24 hours of STEMI was similar in the two groups [<a href="#rid124">124</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In two studies, <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> and <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> response was evaluated by VerifyNow assay in patients undergoing elective PCI. Poor responders to aspirin or clopidogrel were treated with a glycoprotein (GP) IIb/IIIa receptor inhibitor which decreased 30-day as well as one-year post-PCI ischemic events without increased bleeding rates [<a href="#rid125">125,126</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Previous large scale studies of personalized antiplatelet therapy that used the VerifyNow P2Y<sub>12</sub> assay mainly recruited low-risk patients undergoing PCI and mostly used the suboptimal therapy of 150 mg daily <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> to overcome HPR [<a href="#rid6">6,106,108</a>]. The latter studies failed to demonstrate the utility of personalization of antiplatelet therapy. In a study of 714 patients with ACS undergoing PCI, platelet function was measured by Multiplate analyzer, and patients with HPR on standard clopidogrel therapy were treated with high-dose clopidogrel or <a class="drug drug_general" data-topicid="9533" href="/d/drug information/9533.html" rel="external">prasugrel</a> at the discretion of the treating physician. In this study, the risk of all-cause death, myocardial infarction, stent thrombosis, or stroke at one year was higher in the high-dose clopidogrel group compared to patients without HPR (HR 2.27, 95% CI 1.45-3.55), whereas outcomes were similar between the prasugrel treated group and patients without HPR (HR 0.90, 95% CI 0.44-1.81) [<a href="#rid127">127</a>]. The latter outcomes were associated with significantly lower platelet reactivity in the prasugrel treated group compared with the high-dose clopidogrel treated group (p&lt;0.0001). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The TROPICAL ACS trial, discussed elsewhere, provides some additional evidence for switching P2Y<sub>12</sub> receptor blockers in patients with an ACS. (See  <a class="medical medical_review" href="/d/html/95.html" rel="external">"Acute non-ST-elevation acute coronary syndromes: Early antiplatelet therapy", section on 'Switching from ticagrelor or prasugrel to clopidogrel'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A randomized, pharmacodynamic trial of <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> 300 mg daily, <a class="drug drug_general" data-topicid="16784" href="/d/drug information/16784.html" rel="external">ticagrelor</a> 90 mg twice daily, or ticagrelor 60 mg twice daily in 162 aspirin-treated stable patients who underwent PCI found the following [<a href="#rid128">128</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Both maintenance doses of <a class="drug drug_general" data-topicid="16784" href="/d/drug information/16784.html" rel="external">ticagrelor</a> achieved more potent and consistent platelet inhibition than <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> at one month.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>There was no impact of <a class="drug drug_general" data-topicid="16784" href="/d/drug information/16784.html" rel="external">ticagrelor</a> on in vitro adenosine uptake or adenosine plasma levels with either ticagrelor dose compared with <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A genotyping substudy of TROPIC ACS revealed that C<em>YP2C19*2</em> and <em>CYP2C19*17</em> carrier status in rapid metabolizers correlates with platelet reactivity in ACS patients on <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a>. Based on these results, the authors suggested that CYP2C19 genotyping can play a valuable role for preselecting patients who will and who may not be suitable for early guided deescalation of antiplatelet treatment. They also demonstrated that in patients treated with platelet-function-guided deescalation strategy, genotyping may not provide added benefit in predicting ischemic or bleeding risk [<a href="#rid129">129</a>]. </p><p></p><p>The CREATIVE trial presented above suggests that triple therapy with <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a>, <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a>, and <a class="drug drug_general" data-topicid="8872" href="/d/drug information/8872.html" rel="external">cilostazol</a> may be beneficial. (See <a class="local">'Adjusting the maintenance dose'</a> above.)</p><p>In the HOST-REDUCE-POLYTECH-ACS trial, conducted in South Korea, 2338 ACS patients undergoing PCI were randomly assigned to the de-escalation strategy of 10 mg <a class="drug drug_general" data-topicid="9533" href="/d/drug information/9533.html" rel="external">prasugrel</a> for one month followed by 5 mg prasugrel versus conventional strategy of 10 mg prasugrel for one year in addition to 100 mg <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> in both groups. The primary endpoint of net adverse clinical events (all-cause death, nonfatal MI, stent thrombosis, repeat revascularization, stroke, and bleeding events of grade 2 or higher according to Bleeding Academic Research Consortium [BARC] criteria) was similar between groups (Kaplan-Meier estimate 7.2 percent in the de-escalation group and 10.1 percent in the conventional group, a statistically significant reduction [HR 0.70, 95% CI 0.52-0.92; p equivalence = 0.012]). Ischemic risk was similar between the groups (HR 0.76, 95% CI 0.40-1.45; p = 0.40) while bleeding risk was significantly decreased in the de-escalation group (HR 0.48, 95% CI 0.32-0.73; p = 0.0007).</p><p class="headingAnchor" id="H265021676"><span class="h2">Stent thrombosis</span><span class="headingEndMark"> — </span>The approach to additional antiplatelet therapy in patients with stent thrombosis taking <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> is presented separately. (See  <a class="medical medical_review" href="/d/html/87310.html" rel="external">"Coronary artery stent thrombosis: Clinical presentation and management", section on 'Long-term antiplatelet therapy'</a>.) </p><p class="headingAnchor" id="H86718632"><span class="h1">LOW PLATELET REACTIVITY AND BLEEDING</span><span class="headingEndMark"> — </span>While dual antiplatelet therapy (DAT) lowers the risk of ischemic events in patients undergoing percutaneous coronary intervention, the risk of bleeding is increased, particularly when more potent P2Y<sub>12</sub> receptor inhibitors are used. In this setting, low platelet reactivity (LPR) is associated with an increased risk of bleeding. A consensus document highlighting the above observations with a therapeutic window concept and updated cutoffs for high on-treatment platelet reactivity and LPR for P2Y<sub>12</sub> receptor inhibitor therapy has been published [<a href="#rid130">130</a>]. However, we do not recommend screening for low platelet reactivity, as there are insufficient data to support its use.</p><p>Platelet function testing offers the possibility of discerning the optimal drug choice and dosing strategy for an individual patient. The safety and efficacy of early de-escalation of antiplatelet treatment from <a class="drug drug_general" data-topicid="9533" href="/d/drug information/9533.html" rel="external">prasugrel</a> to <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> guided by platelet function testing was investigated in the open-label, assessor-blinded, TROPICAL-ACS trial, which is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/94.html" rel="external">"Acute ST-elevation myocardial infarction: Antiplatelet therapy", section on 'Switching from ticagrelor or prasugrel to clopidogrel'</a>.)</p><p class="headingAnchor" id="H352546565"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/114034.html" rel="external">"Society guideline links: Non-ST-elevation acute coronary syndromes (non-ST-elevation myocardial infarction)"</a> and  <a class="medical medical_society_guidelines" href="/d/html/113180.html" rel="external">"Society guideline links: ST-elevation myocardial infarction (STEMI)"</a>.) </p><p class="headingAnchor" id="H41"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>"Resistance" or "nonresponsiveness/hyporesponsiveness" to an antiplatelet drug is a pharmacodynamic phenomenon in which there is no significant reduction in platelet function after treatment as compared to the baseline. High on-treatment platelet reactivity (HPR) is a similar concept and indicates persistent response of the P2Y<sub>12</sub> receptor (<a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> target) based on one measurement of on-treatment platelet reactivity. (See <a class="local">'Definitions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Most, but not all, studies have found a positive association between patients with hypo-/nonresponsiveness or HPR and subsequent thrombotic/ischemic events after percutaneous coronary intervention. (See <a class="local">'HPR and thrombotic events'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">Clopidogrel</a> treatment failure is the occurrence of a thrombotic/ischemic event during clopidogrel therapy in patients with heightened platelet reactivity (HPR). These events are usually stent thrombosis or recurrent acute coronary syndrome (ACS). (See <a class="local">'Clinical manifestations and diagnosis'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients who have been started on <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a>, we do not routinely test patients for clopidogrel resistance with genetic testing to detect loss of function gene carriers (eg, CYP2C19 allele testing) or with platelet function testing to detect P2Y<sub>12</sub> resistance. (See <a class="local">'Screening'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The optimal approach to patients taking <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> for a prior ACS (without stenting) who develop a subsequent ACS is not known. For these patients, we suggest switching from clopidogrel to a more potent platelet P2Y<sub>12</sub> receptor blocker rather than any other strategy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Management of possible clopidogrel failure'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Our approach to patients taking <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> who develop stent thrombosis is discussed separately. (See  <a class="medical medical_review" href="/d/html/87310.html" rel="external">"Coronary artery stent thrombosis: Clinical presentation and management", section on 'Long-term antiplatelet therapy'</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Bonello L, Tantry US, Marcucci R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010; 56:919.</a></li><li><a class="nounderline abstract_t">Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107:2908.</a></li><li><a class="nounderline abstract_t">Michelson AD, Linden MD, Furman MI, et al. Evidence that pre-existent variability in platelet response to ADP accounts for 'clopidogrel resistance'. J Thromb Haemost 2007; 5:75.</a></li><li><a class="nounderline abstract_t">Frelinger AL 3rd, Michelson AD, Wiviott SD, et al. Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel. Results from PRINCIPLE-TIMI 44. Thromb Haemost 2011; 106:219.</a></li><li><a class="nounderline abstract_t">Gachet C, Aleil B, Testing antiplatelet therapy. Eur Heart J 2008; 10(Suppl A):A28.</a></li><li><a class="nounderline abstract_t">Price MJ, Berger PB, Teirstein PS, et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 2011; 305:1097.</a></li><li><a class="nounderline abstract_t">Campo G, Parrinello G, Ferraresi P, et al. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol 2011; 57:2474.</a></li><li><a class="nounderline abstract_t">Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 2009; 120:2577.</a></li><li><a class="nounderline abstract_t">Codner P, Vaduganathan M, Rechavia E, et al. Clopidogrel response up to six months after acute myocardial infarction. Am J Cardiol 2012; 110:321.</a></li><li><a class="nounderline abstract_t">Lewis JP, Fisch AS, Ryan K, et al. Paraoxonase 1 (PON1) gene variants are not associated with clopidogrel response. Clin Pharmacol Ther 2011; 90:568.</a></li><li><a class="nounderline abstract_t">Hagihara K, Kazui M, Kurihara A, et al. A possible mechanism for the differences in efficiency and variability of active metabolite formation from thienopyridine antiplatelet agents, prasugrel and clopidogrel. Drug Metab Dispos 2009; 37:2145.</a></li><li><a class="nounderline abstract_t">Scott SA, Sangkuhl K, Gardner EE, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther 2011; 90:328.</a></li><li><a class="nounderline abstract_t">Hulot JS, Bura A, Villard E, et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006; 108:2244.</a></li><li><a class="nounderline abstract_t">Gurbel PA, Shuldiner AR, Bliden KP, et al. The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy. Am Heart J 2011; 161:598.</a></li><li><a class="nounderline abstract_t">Scott SA, Sangkuhl K, Stein CM, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther 2013; 94:317.</a></li><li><a class="nounderline abstract_t">Levine GN, Jeong YH, Goto S, et al. Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. Nat Rev Cardiol 2014; 11:597.</a></li><li><a class="nounderline abstract_t">Saw J, Brennan DM, Steinhubl SR, et al. Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial. J Am Coll Cardiol 2007; 50:291.</a></li><li><a class="nounderline abstract_t">Trenk D, Hochholzer W, Frundi D, et al. Impact of cytochrome P450 3A4-metabolized statins on the antiplatelet effect of a 600-mg loading dose clopidogrel and on clinical outcome in patients undergoing elective coronary stent placement. Thromb Haemost 2008; 99:174.</a></li><li><a class="nounderline abstract_t">Schmidt M, Johansen MB, Maeng M, et al. Concomitant use of clopidogrel and statins and risk of major adverse cardiovascular events following coronary stent implantation. Br J Clin Pharmacol 2012; 74:161.</a></li><li class="breakAll">Information for Healthcare Professionals: Update to the labeling of Clopidogrel Bisulfate (marketed as Plavix) to alert healthcare professionals about a drug interaction with omeprazole (marketed as Prilosec and Prilosec OTC). Available on the US Food and Drug Administration (FDA) web site: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm190848.htm (Accessed on November 18, 2009).</li><li class="breakAll">FDA's MedWatch Safety Alerts: November 2009. Plavix and Prilosec Drug Interaction. Available at: http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm192103.htm#PlavixandPrilosecDrugInteraction (Accessed on January 26, 2009).</li><li><a class="nounderline abstract_t">Tantry US, Kereiakes DJ, Gurbel PA. Clopidogrel and proton pump inhibitors: influence of pharmacological interactions on clinical outcomes and mechanistic explanations. JACC Cardiovasc Interv 2011; 4:365.</a></li><li><a class="nounderline abstract_t">Focks JJ, Brouwer MA, van Oijen MG, et al. Concomitant use of clopidogrel and proton pump inhibitors: impact on platelet function and clinical outcome- a systematic review. Heart 2013; 99:520.</a></li><li><a class="nounderline abstract_t">Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010; 363:1909.</a></li><li><a class="nounderline abstract_t">Goodman SG, Clare R, Pieper KS, et al. Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial. Circulation 2012; 125:978.</a></li><li><a class="nounderline abstract_t">Demcsák A, Lantos T, Bálint ER, et al. PPIs Are Not Responsible for Elevating Cardiovascular Risk in Patients on Clopidogrel-A Systematic Review and Meta-Analysis. Front Physiol 2018; 9:1550.</a></li><li><a class="nounderline abstract_t">Gremmel T, Steiner S, Seidinger D, et al. Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition. Heart 2010; 96:186.</a></li><li><a class="nounderline abstract_t">Siller-Matula JM, Lang I, Christ G, Jilma B. Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. J Am Coll Cardiol 2008; 52:1557.</a></li><li><a class="nounderline abstract_t">Olesen JB, Gislason GH, Charlot MG, et al. Calcium-channel blockers do not alter the clinical efficacy of clopidogrel after myocardial infarction: a nationwide cohort study. J Am Coll Cardiol 2011; 57:409.</a></li><li><a class="nounderline abstract_t">Sarafoff N, Neumann L, Morath T, et al. Lack of impact of calcium-channel blockers on the pharmacodynamic effect and the clinical efficacy of clopidogrel after drug-eluting stenting. Am Heart J 2011; 161:605.</a></li><li><a class="nounderline abstract_t">Good CW, Steinhubl SR, Brennan DM, et al. Is there a clinically significant interaction between calcium channel antagonists and clopidogrel?: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Circ Cardiovasc Interv 2012; 5:77.</a></li><li><a class="nounderline abstract_t">Lau WC, Gurbel PA, Watkins PB, et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 2004; 109:166.</a></li><li><a class="nounderline abstract_t">Judge HM, Patil SB, Buckland RJ, et al. Potentiation of clopidogrel active metabolite formation by rifampicin leads to greater P2Y12 receptor blockade and inhibition of platelet aggregation after clopidogrel. J Thromb Haemost 2010; 8:1820.</a></li><li><a class="nounderline abstract_t">Lau WC, Welch TD, Shields T, et al. The effect of St John's Wort on the pharmacodynamic response of clopidogrel in hyporesponsive volunteers and patients: increased platelet inhibition by enhancement of CYP3A4 metabolic activity. J Cardiovasc Pharmacol 2011; 57:86.</a></li><li><a class="nounderline abstract_t">Gajos G, Rostoff P, Undas A, Piwowarska W. Effects of polyunsaturated omega-3 fatty acids on responsiveness to dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: the OMEGA-PCI (OMEGA-3 fatty acids after pci to modify responsiveness to dual antiplatelet therapy) study. J Am Coll Cardiol 2010; 55:1671.</a></li><li><a class="nounderline abstract_t">Bouman HJ, van Werkum JW, Hackeng CM, et al. The importance of anticoagulant agents in measuring platelet aggregation in patients treated with clopidogrel and aspirin. J Thromb Haemost 2008; 6:1040.</a></li><li><a class="nounderline abstract_t">Duzenli MA, Ozdemir K, Aygul N, et al. Comparison of increased aspirin dose versus combined aspirin plus clopidogrel therapy in patients with diabetes mellitus and coronary heart disease and impaired antiplatelet response to low-dose aspirin. Am J Cardiol 2008; 102:396.</a></li><li><a class="nounderline abstract_t">Angiolillo DJ, Bernardo E, Zanoni M, et al. Impact of insulin receptor substrate-1 genotypes on platelet reactivity and cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 2011; 58:30.</a></li><li><a class="nounderline abstract_t">Grove EL, Hvas AM, Kristensen SD. Immature platelets in patients with acute coronary syndromes. Thromb Haemost 2009; 101:151.</a></li><li><a class="nounderline abstract_t">Michos ED, Ardehali R, Blumenthal RS, et al. Aspirin and clopidogrel resistance. Mayo Clin Proc 2006; 81:518.</a></li><li><a class="nounderline abstract_t">Buch AN, Singh S, Roy P, et al. Measuring aspirin resistance, clopidogrel responsiveness, and postprocedural markers of myonecrosis in patients undergoing percutaneous coronary intervention. Am J Cardiol 2007; 99:1518.</a></li><li><a class="nounderline abstract_t">Price MJ, Nayak KR, Barker CM, et al. Predictors of heightened platelet reactivity despite dual-antiplatelet therapy in patients undergoing percutaneous coronary intervention. Am J Cardiol 2009; 103:1339.</a></li><li><a class="nounderline abstract_t">Labarthe B, Théroux P, Angioï M, Ghitescu M. Matching the evaluation of the clinical efficacy of clopidogrel to platelet function tests relevant to the biological properties of the drug. J Am Coll Cardiol 2005; 46:638.</a></li><li><a class="nounderline abstract_t">Erlinge D, Varenhorst C, Braun OO, et al. Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo. J Am Coll Cardiol 2008; 52:1968.</a></li><li><a class="nounderline abstract_t">Gaborit B, Frère C, Cuisset T, et al. Enhanced post-clopidogrel platelet reactivity in diabetic patients is independently related to plasma fibrinogen level but not to glycemic control. J Thromb Haemost 2009; 7:1939.</a></li><li><a class="nounderline abstract_t">Morel O, El Ghannudi S, Hess S, et al. The extent of P2Y12 inhibition by clopidogrel in diabetes mellitus patients with acute coronary syndrome is not related to glycaemic control: roles of white blood cell count and body weight. Thromb Haemost 2012; 108:338.</a></li><li><a class="nounderline abstract_t">Angiolillo DJ, Bernardo E, Capodanno D, et al. Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy. J Am Coll Cardiol 2010; 55:1139.</a></li><li><a class="nounderline abstract_t">Mangiacapra F, Patti G, Peace A, et al. Comparison of platelet reactivity and periprocedural outcomes in patients with versus without diabetes mellitus and treated with clopidogrel and percutaneous coronary intervention. Am J Cardiol 2010; 106:619.</a></li><li><a class="nounderline abstract_t">Frelinger AL 3rd, Michelson AD. Clopidogrel linking evaluation of platelet response variability to mechanism of action. J Am Coll Cardiol 2005; 46:646.</a></li><li><a class="nounderline abstract_t">Siller-Matula J, Schrör K, Wojta J, Huber K. Thienopyridines in cardiovascular disease: focus on clopidogrel resistance. Thromb Haemost 2007; 97:385.</a></li><li><a class="nounderline abstract_t">Montalescot G, Sideris G, Cohen R, et al. Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study. Thromb Haemost 2010; 103:213.</a></li><li><a class="nounderline abstract_t">Storey RF, Husted S, Harrington RA, et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol 2007; 50:1852.</a></li><li><a class="nounderline abstract_t">James S, Akerblom A, Cannon CP, et al. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J 2009; 157:599.</a></li><li><a class="nounderline abstract_t">Gurbel PA, Bliden KP, Butler K, et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation 2010; 121:1188.</a></li><li><a class="nounderline abstract_t">Wallentin L, James S, Storey RF, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 2010; 376:1320.</a></li><li><a class="nounderline abstract_t">Morel O, El Ghannudi S, Jesel L, et al. Cardiovascular mortality in chronic kidney disease patients undergoing percutaneous coronary intervention is mainly related to impaired P2Y12 inhibition by clopidogrel. J Am Coll Cardiol 2011; 57:399.</a></li><li><a class="nounderline abstract_t">Muller C, Caillard S, Jesel L, et al. Association of estimated GFR with platelet inhibition in patients treated with clopidogrel. Am J Kidney Dis 2012; 59:777.</a></li><li><a class="nounderline abstract_t">Kolandaivelu K, Bhatt DL. Overcoming 'resistance' to antiplatelet therapy: targeting the issue of nonadherence. Nat Rev Cardiol 2010; 7:461.</a></li><li><a class="nounderline abstract_t">Hamann GF, Weimar C, Glahn J, et al. Adherence to secondary stroke prevention strategies--results from the German Stroke Data Bank. Cerebrovasc Dis 2003; 15:282.</a></li><li><a class="nounderline abstract_t">Desai NR, Mega JL, Jiang S, et al. Interaction between cigarette smoking and clinical benefit of clopidogrel. J Am Coll Cardiol 2009; 53:1273.</a></li><li><a class="nounderline abstract_t">Mehta SR, Tanguay JF, Eikelboom JW, et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet 2010; 376:1233.</a></li><li><a class="nounderline abstract_t">Gurbel PA, Nolin TD, Tantry US. Clopidogrel efficacy and cigarette smoking status. JAMA 2012; 307:2495.</a></li><li><a class="nounderline abstract_t">Gagne JJ, Bykov K, Choudhry NK, et al. Effect of smoking on comparative efficacy of antiplatelet agents: systematic review, meta-analysis, and indirect comparison. BMJ 2013; 347:f5307.</a></li><li><a class="nounderline abstract_t">Hasford J, Bramlage P, Koch G, et al. Inconsistent trial assessments by the National Institute for Health and Clinical Excellence and IQWiG: standards for the performance and interpretation of subgroup analyses are needed. J Clin Epidemiol 2010; 63:1298.</a></li><li><a class="nounderline abstract_t">Saraff KY. Smoking influences the effectiveness of dual antiplatelet therapy on long-term outcomes following PCI. J Am Coll Cardiol 2006; 47:36B.</a></li><li><a class="nounderline abstract_t">Bliden KP, Dichiara J, Lawal L, et al. The association of cigarette smoking with enhanced platelet inhibition by clopidogrel. J Am Coll Cardiol 2008; 52:531.</a></li><li><a class="nounderline abstract_t">Park KW, Kang SH, Kang J, et al. Enhanced clopidogrel response in smokers is reversed after discontinuation as assessed by VerifyNow assay: additional evidence for the concept of 'smokers' paradox'. Heart 2012; 98:1000.</a></li><li><a class="nounderline abstract_t">Gurbel PA, Bliden KP, Logan DK, et al. The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study. J Am Coll Cardiol 2013; 62:505.</a></li><li><a class="nounderline abstract_t">Gurbel PA, Baker BA, Bailey WL, et al. Unravelling the smokers' paradox: cigarette smoking, high-risk coronary artery disease and enhanced clinical efficacy of oral P2Y₁₂ inhibitors. Thromb Haemost 2014; 111:1187.</a></li><li><a class="nounderline abstract_t">Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109:3171.</a></li><li><a class="nounderline abstract_t">Gurbel PA, Bliden KP, Guyer K, et al. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. J Am Coll Cardiol 2005; 46:1820.</a></li><li><a class="nounderline abstract_t">Gurbel PA, Antonino MJ, Bliden KP, et al. Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: a potential antiplatelet therapeutic target. Platelets 2008; 19:595.</a></li><li><a class="nounderline abstract_t">Gurbel PA, Bliden KP, Samara W, et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. J Am Coll Cardiol 2005; 46:1827.</a></li><li><a class="nounderline abstract_t">Price MJ, Endemann S, Gollapudi RR, et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 2008; 29:992.</a></li><li><a class="nounderline abstract_t">Sibbing D, Braun S, Morath T, et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 2009; 53:849.</a></li><li><a class="nounderline abstract_t">Hochholzer W, Trenk D, Bestehorn HP, et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006; 48:1742.</a></li><li><a class="nounderline abstract_t">Marcucci R, Gori AM, Paniccia R, et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation 2009; 119:237.</a></li><li><a class="nounderline abstract_t">Brar SS, ten Berg J, Marcucci R, et al. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data. J Am Coll Cardiol 2011; 58:1945.</a></li><li><a class="nounderline abstract_t">Stone GW, Witzenbichler B, Weisz G, et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet 2013; 382:614.</a></li><li><a class="nounderline abstract_t">Kirtane AJ, Parikh PB, Stuckey TD, et al. Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in Patients Undergoing Percutaneous Coronary Intervention?: "Window" Analysis From the ADAPT-DES Study (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents). JACC Cardiovasc Interv 2015; 8:1978.</a></li><li><a class="nounderline abstract_t">Yun KH, Mintz GS, Witzenbichler B, et al. Relationship Between Platelet Reactivity and Culprit Lesion Morphology: An Assessment From the ADAPT-DES Intravascular Ultrasound Substudy. JACC Cardiovasc Imaging 2016; 9:849.</a></li><li><a class="nounderline abstract_t">Weisz G, Smilowitz NR, Kirtane AJ, et al. Proton Pump Inhibitors, Platelet Reactivity, and Cardiovascular Outcomes After Drug-Eluting Stents in Clopidogrel-Treated Patients: The ADAPT-DES Study. Circ Cardiovasc Interv 2015; 8.</a></li><li><a class="nounderline abstract_t">Stuckey TD, Kirtane AJ, Brodie BR, et al. Impact of Aspirin and Clopidogrel Hyporesponsiveness in Patients Treated With Drug-Eluting Stents: 2-Year Results of a Prospective, Multicenter Registry Study. JACC Cardiovasc Interv 2017; 10:1607.</a></li><li><a class="nounderline abstract_t">Gurbel PA, Tantry US. Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents?: platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents. Circulation 2012; 125:1276.</a></li><li><a class="nounderline abstract_t">Reny JL, Fontana P, Hochholzer W, et al. Vascular risk levels affect the predictive value of platelet reactivity for the occurrence of MACE in patients on clopidogrel. Systematic review and meta-analysis of individual patient data. Thromb Haemost 2016; 115:844.</a></li><li><a class="nounderline abstract_t">Hennekens CH, DeMets D. Statistical association and causation: contributions of different types of evidence. JAMA 2011; 305:1134.</a></li><li class="breakAll">Henneckens CH, Buring JE. Epidemiology in Medicine, Little Brown, Boston 1987.</li><li><a class="nounderline abstract_t">Spiliopoulos S, Pastromas G, Katsanos K, et al. Platelet responsiveness to clopidogrel treatment after peripheral endovascular procedures: the PRECLOP study: clinical impact and optimal cutoff value of on-treatment high platelet reactivity. J Am Coll Cardiol 2013; 61:2428.</a></li><li><a class="nounderline abstract_t">Gurbel PA, Erlinge D, Ohman EM, et al. Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy. JAMA 2012; 308:1785.</a></li><li><a class="nounderline abstract_t">Reny JL, Berdagué P, Poncet A, et al. Antiplatelet drug response status does not predict recurrent ischemic events in stable cardiovascular patients: results of the Antiplatelet Drug Resistances and Ischemic Events study. Circulation 2012; 125:3201.</a></li><li><a class="nounderline abstract_t">Cavallari LH, Lee CR, Beitelshees AL, et al. Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. JACC Cardiovasc Interv 2018; 11:181.</a></li><li><a class="nounderline abstract_t">Pereira NL, Rihal C, Lennon R, et al. Effect of CYP2C19 Genotype on Ischemic Outcomes During Oral P2Y12 Inhibitor Therapy: A Meta-Analysis. JACC Cardiovasc Interv 2021; 14:739.</a></li><li><a class="nounderline abstract_t">Wang Y, Pan Y, Zhao X, et al. Clopidogrel With Aspirin in Acute Minor Stroke or Transient Ischemic Attack (CHANCE) Trial: One-Year Outcomes. Circulation 2015; 132:40.</a></li><li><a class="nounderline abstract_t">Wang Y, Zhao X, Lin J, et al. Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack. JAMA 2016; 316:70.</a></li><li><a class="nounderline abstract_t">Meschia JF, Walton RL, Farrugia LP, et al. Efficacy of Clopidogrel for Prevention of Stroke Based on CYP2C19 Allele Status in the POINT Trial. Stroke 2020; 51:2058.</a></li><li><a class="nounderline abstract_t">Gurbel PA, Becker RC, Mann KG, et al. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol 2007; 50:1822.</a></li><li><a class="nounderline abstract_t">Breet NJ, van Werkum JW, Bouman HJ, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 2010; 303:754.</a></li><li><a class="nounderline abstract_t">Geisler T, Grass D, Bigalke B, et al. The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score. J Thromb Haemost 2008; 6:54.</a></li><li><a class="nounderline abstract_t">Sibbing D, Aradi D, Alexopoulos D, et al. Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention. JACC Cardiovasc Interv 2019; 12:1521.</a></li><li><a class="nounderline abstract_t">Bauer T, Bouman HJ, van Werkum JW, et al. Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis. BMJ 2011; 343:d4588.</a></li><li><a class="nounderline abstract_t">Nissen SE. Pharmacogenomics and clopidogrel: irrational exuberance? JAMA 2011; 306:2727.</a></li><li><a class="nounderline abstract_t">Pereira NL, Farkouh ME, So D, et al. Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial. JAMA 2020; 324:761.</a></li><li><a class="nounderline abstract_t">Claassens DMF, Vos GJA, Bergmeijer TO, et al. A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI. N Engl J Med 2019; 381:1621.</a></li><li><a class="nounderline abstract_t">Notarangelo FM, Maglietta G, Bevilacqua P, et al. Pharmacogenomic approach to selecting antiplatelet therapy in patients with acute coronary Syndromes: The PHARMCLO Trial. J Am Coll Cardiol 2018; 71:1869.</a></li><li><a class="nounderline abstract_t">Montalescot G, Rangé G, Silvain J, et al. High on-treatment platelet reactivity as a risk factor for secondary prevention after coronary stent revascularization: A landmark analysis of the ARCTIC study. Circulation 2014; 129:2136.</a></li><li><a class="nounderline abstract_t">Collet JP, Cuisset T, Rangé G, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 2012; 367:2100.</a></li><li><a class="nounderline abstract_t">Cayla G, Cuisset T, Silvain J, et al. Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial. Lancet 2016; 388:2015.</a></li><li><a class="nounderline abstract_t">Trenk D, Stone GW, Gawaz M, et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. J Am Coll Cardiol 2012; 59:2159.</a></li><li><a class="nounderline abstract_t">Gurbel PA, Bliden KP, Hayes KM, et al. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol 2005; 45:1392.</a></li><li><a class="nounderline abstract_t">Patti G, Colonna G, Pasceri V, et al. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2005; 111:2099.</a></li><li><a class="nounderline abstract_t">Bonello L, Camoin-Jau L, Arques S, et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol 2008; 51:1404.</a></li><li><a class="nounderline abstract_t">L'Allier PL, Ducrocq G, Pranno N, et al. Clopidogrel 600-mg double loading dose achieves stronger platelet inhibition than conventional regimens: results from the PREPAIR randomized study. J Am Coll Cardiol 2008; 51:1066.</a></li><li><a class="nounderline abstract_t">Gladding P, Webster M, Zeng I, et al. The antiplatelet effect of higher loading and maintenance dose regimens of clopidogrel: the PRINC (Plavix Response in Coronary Intervention) trial. JACC Cardiovasc Interv 2008; 1:612.</a></li><li><a class="nounderline abstract_t">Gladding P, Webster M, Zeng I, et al. The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial. JACC Cardiovasc Interv 2008; 1:620.</a></li><li><a class="nounderline abstract_t">Aleil B, Jacquemin L, De Poli F, et al. Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study. JACC Cardiovasc Interv 2008; 1:631.</a></li><li><a class="nounderline abstract_t">Bonello L, Armero S, Ait Mokhtar O, et al. Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2C19*2 loss of function polymorphism. J Am Coll Cardiol 2010; 56:1630.</a></li><li><a class="nounderline abstract_t">Gurbel PA, Tantry US. An initial experiment with personalized antiplatelet therapy: the GRAVITAS trial. JAMA 2011; 305:1136.</a></li><li><a class="nounderline abstract_t">Price MJ, Angiolillo DJ, Teirstein PS, et al. Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial. Circulation 2011; 124:1132.</a></li><li><a class="nounderline abstract_t">Tang YD, Wang W, Yang M, et al. Randomized Comparisons of Double-Dose Clopidogrel or Adjunctive Cilostazol Versus Standard Dual Antiplatelet in Patients With High Posttreatment Platelet Reactivity: Results of the CREATIVE Trial. Circulation 2018; 137:2231.</a></li><li><a class="nounderline abstract_t">Mega JL, Hochholzer W, Frelinger AL 3rd, et al. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA 2011; 306:2221.</a></li><li><a class="nounderline abstract_t">Bliden KP, Tantry US, Storey RF, et al. The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: combined analysis of the ONSET/OFFSET and RESPOND studies. Am Heart J 2011; 162:160.</a></li><li><a class="nounderline abstract_t">Roberts JD, Wells GA, Le May MR, et al. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. Lancet 2012; 379:1705.</a></li><li><a class="nounderline abstract_t">Alexopoulos D, Dimitropoulos G, Davlouros P, et al. Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: the importance of CYP2C19*2 genotyping. JACC Cardiovasc Interv 2011; 4:403.</a></li><li><a class="nounderline abstract_t">Alexopoulos D, Xanthopoulou I, Gkizas V, et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv 2012; 5:797.</a></li><li><a class="nounderline abstract_t">Campo G, Fileti L, de Cesare N, et al. Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel) trial substudy. J Am Coll Cardiol 2010; 56:1447.</a></li><li><a class="nounderline abstract_t">Cuisset T, Frere C, Quilici J, et al. Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study. JACC Cardiovasc Interv 2008; 1:649.</a></li><li><a class="nounderline abstract_t">Aradi D, Tornyos A, Pintér T, et al. Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel. J Am Coll Cardiol 2014; 63:1061.</a></li><li><a class="nounderline abstract_t">Orme RC, Parker WAE, Thomas MR, et al. Study of Two Dose Regimens of Ticagrelor Compared With Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention for Stable Coronary Artery Disease. Circulation 2018; 138:1290.</a></li><li><a class="nounderline abstract_t">Gross L, Trenk D, Jacobshagen C, et al. Genotype-Phenotype Association and Impact on Outcomes following Guided De-Escalation of Anti-Platelet Treatment in Acute Coronary Syndrome Patients: The TROPICAL-ACS Genotyping Substudy. Thromb Haemost 2018; 118:1656.</a></li><li><a class="nounderline abstract_t">Tantry US, Bonello L, Aradi D, et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 2013; 62:2261.</a></li></ol></div><div id="topicVersionRevision">Topic 6684 Version 105.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20828644" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12796140" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17002661" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Evidence that pre-existent variability in platelet response to ADP accounts for 'clopidogrel resistance'.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21713327" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel. Results from PRINCIPLE-TIMI 44.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Gachet C, Aleil B, Testing antiplatelet therapy</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21406646" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21679849" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19923168" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22534051" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Clopidogrel response up to six months after acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21881565" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Paraoxonase 1 (PON1) gene variants are not associated with clopidogrel response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19704027" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : A possible mechanism for the differences in efficiency and variability of active metabolite formation from thienopyridine antiplatelet agents, prasugrel and clopidogrel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21716271" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16772608" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21392617" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23698643" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25154978" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17659194" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18217151" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Impact of cytochrome P450 3A4-metabolized statins on the antiplatelet effect of a 600-mg loading dose clopidogrel and on clinical outcome in patients undergoing elective coronary stent placement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22243420" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Concomitant use of clopidogrel and statins and risk of major adverse cardiovascular events following coronary stent implantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22243420" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Concomitant use of clopidogrel and statins and risk of major adverse cardiovascular events following coronary stent implantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22243420" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Concomitant use of clopidogrel and statins and risk of major adverse cardiovascular events following coronary stent implantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21511216" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Clopidogrel and proton pump inhibitors: influence of pharmacological interactions on clinical outcomes and mechanistic explanations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22851683" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Concomitant use of clopidogrel and proton pump inhibitors: impact on platelet function and clinical outcome- a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20925534" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Clopidogrel with or without omeprazole in coronary artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22261200" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30510515" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : PPIs Are Not Responsible for Elevating Cardiovascular Risk in Patients on Clopidogrel-A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19687016" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19007592" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Calcium-channel blockers reduce the antiplatelet effect of clopidogrel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21251580" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Calcium-channel blockers do not alter the clinical efficacy of clopidogrel after myocardial infarction: a nationwide cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21392618" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Lack of impact of calcium-channel blockers on the pharmacodynamic effect and the clinical efficacy of clopidogrel after drug-eluting stenting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22319066" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Is there a clinically significant interaction between calcium channel antagonists and clopidogrel?: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14707025" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20492465" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Potentiation of clopidogrel active metabolite formation by rifampicin leads to greater P2Y12 receptor blockade and inhibition of platelet aggregation after clopidogrel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20980920" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The effect of St John's Wort on the pharmacodynamic response of clopidogrel in hyporesponsive volunteers and patients: increased platelet inhibition by enhancement of CYP3A4 metabolic activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20394870" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Effects of polyunsaturated omega-3 fatty acids on responsiveness to dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: the OMEGA-PCI (OMEGA-3 fatty acids after pci to modify responsiveness to dual antiplatelet therapy) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18394013" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : The importance of anticoagulant agents in measuring platelet aggregation in patients treated with clopidogrel and aspirin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18678294" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Comparison of increased aspirin dose versus combined aspirin plus clopidogrel therapy in patients with diabetes mellitus and coronary heart disease and impaired antiplatelet response to low-dose aspirin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21700086" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Impact of insulin receptor substrate-1 genotypes on platelet reactivity and cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19132202" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Immature platelets in patients with acute coronary syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16610572" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Aspirin and clopidogrel resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17531573" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Measuring aspirin resistance, clopidogrel responsiveness, and postprocedural markers of myonecrosis in patients undergoing percutaneous coronary intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19427425" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Predictors of heightened platelet reactivity despite dual-antiplatelet therapy in patients undergoing percutaneous coronary intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16098428" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Matching the evaluation of the clinical efficacy of clopidogrel to platelet function tests relevant to the biological properties of the drug.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19055987" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20015321" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Enhanced post-clopidogrel platelet reactivity in diabetic patients is independently related to plasma fibrinogen level but not to glycemic control.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22740070" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : The extent of P2Y12 inhibition by clopidogrel in diabetes mellitus patients with acute coronary syndrome is not related to glycaemic control: roles of white blood cell count and body weight.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20223369" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20723634" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Comparison of platelet reactivity and periprocedural outcomes in patients with versus without diabetes mellitus and treated with clopidogrel and percutaneous coronary intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16098429" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Clopidogrel linking evaluation of platelet response variability to mechanism of action.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17334505" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Thienopyridines in cardiovascular disease: focus on clopidogrel resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20062936" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17980251" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19332184" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20194878" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20801498" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21251579" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Cardiovascular mortality in chronic kidney disease patients undergoing percutaneous coronary intervention is mainly related to impaired P2Y12 inhibition by clopidogrel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22425260" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Association of estimated GFR with platelet inhibition in patients treated with clopidogrel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20517286" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Overcoming 'resistance' to antiplatelet therapy: targeting the issue of nonadherence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12686793" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Adherence to secondary stroke prevention strategies--results from the German Stroke Data Bank.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19358940" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Interaction between cigarette smoking and clinical benefit of clopidogrel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20817281" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22797448" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Clopidogrel efficacy and cigarette smoking status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24046285" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Effect of smoking on comparative efficacy of antiplatelet agents: systematic review, meta-analysis, and indirect comparison.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20172690" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Inconsistent trial assessments by the National Institute for Health and Clinical Excellence and IQWiG: standards for the performance and interpretation of subgroup analyses are needed.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Smoking influences the effectiveness of dual antiplatelet therapy on long-term outcomes following PCI</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18687246" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : The association of cigarette smoking with enhanced platelet inhibition by clopidogrel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22572048" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Enhanced clopidogrel response in smokers is reversed after discontinuation as assessed by VerifyNow assay: additional evidence for the concept of 'smokers' paradox'.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23602770" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24553730" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Unravelling the smokers' paradox: cigarette smoking, high-risk coronary artery disease and enhanced clinical efficacy of oral P2Y₁₂inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15184279" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16286165" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19012177" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: a potential antiplatelet therapeutic target.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16286166" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18263931" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19264241" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17084243" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19118249" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22032704" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23890998" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26738669" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in Patients Undergoing Percutaneous Coronary Intervention?: "Window" Analysis From the ADAPT-DES Study (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26897675" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Relationship Between Platelet Reactivity and Culprit Lesion Morphology: An Assessment From the ADAPT-DES Intravascular Ultrasound Substudy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26458411" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Proton Pump Inhibitors, Platelet Reactivity, and Cardiovascular Outcomes After Drug-Eluting Stents in Clopidogrel-Treated Patients: The ADAPT-DES Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28780034" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Impact of Aspirin and Clopidogrel Hyporesponsiveness in Patients Treated With Drug-Eluting Stents: 2-Year Results of a Prospective, Multicenter Registry Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22412089" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents?: platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26607655" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Vascular risk levels affect the predictive value of platelet reactivity for the occurrence of MACE in patients on clopidogrel. Systematic review and meta-analysis of individual patient data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21406653" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Statistical association and causation: contributions of different types of evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21406653" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Statistical association and causation: contributions of different types of evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23602777" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Platelet responsiveness to clopidogrel treatment after peripheral endovascular procedures: the PRECLOP study: clinical impact and optimal cutoff value of on-treatment high platelet reactivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23117779" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22615340" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Antiplatelet drug response status does not predict recurrent ischemic events in stable cardiovascular patients: results of the Antiplatelet Drug Resistances and Ischemic Events study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29102571" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33744207" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Effect of CYP2C19 Genotype on Ischemic Outcomes During Oral P2Y12 Inhibitor Therapy: A Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25957224" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Clopidogrel With Aspirin in Acute Minor Stroke or Transient Ischemic Attack (CHANCE) Trial: One-Year Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27348249" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32568642" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Efficacy of Clopidogrel for Prevention of Stroke Based on CYP2C19 Allele Status in the POINT Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17980247" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Platelet function monitoring in patients with coronary artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20179285" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17949474" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31202949" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21816733" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22203545" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Pharmacogenomics and clopidogrel: irrational exuberance?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32840598" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31479209" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29540324" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Pharmacogenomic approach to selecting antiplatelet therapy in patients with acute coronary Syndromes: The PHARMCLO Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24718568" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : High on-treatment platelet reactivity as a risk factor for secondary prevention after coronary stent revascularization: A landmark analysis of the ARCTIC study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23121439" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Bedside monitoring to adjust antiplatelet therapy for coronary stenting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27581531" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22520250" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15862408" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15750189" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18387444" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18342223" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Clopidogrel 600-mg double loading dose achieves stronger platelet inhibition than conventional regimens: results from the PREPAIR randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19463374" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : The antiplatelet effect of higher loading and maintenance dose regimens of clopidogrel: the PRINC (Plavix Response in Coronary Intervention) trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19463375" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19463377" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20708365" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2C19*2 loss of function polymorphism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21406654" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : An initial experiment with personalized antiplatelet therapy: the GRAVITAS trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21875913" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29420189" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Randomized Comparisons of Double-Dose Clopidogrel or Adjunctive Cilostazol Versus Standard Dual Antiplatelet in Patients With High Posttreatment Platelet Reactivity: Results of the CREATIVE Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22088980" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21742103" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: combined analysis of the ONSET/OFFSET and RESPOND studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22464343" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21511219" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: the importance of CYP2C19*2 genotyping.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23169985" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20951320" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel) trial substudy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19463379" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24486281" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29930021" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Study of Two Dose Regimens of Ticagrelor Compared With Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention for Stable Coronary Artery Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30103241" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Genotype-Phenotype Association and Impact on Outcomes following Guided De-Escalation of Anti-Platelet Treatment in Acute Coronary Syndrome Patients: The TROPICAL-ACS Genotyping Substudy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24076493" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
